Today’s routinely recommended vaccines do not cause ADE.

If they did, like

those described above, they would be removed from use. Phase III clinical trials
are designed to uncover frequent or severe side effects before a vaccine is
approved for use. Find out more about how vaccines are developed and approved
for use.
Can the new COVID-19 vaccines cause ADE?
Neither COVID-19 disease nor the new COVID-19 vaccines have shown evidence
of causing ADE. People infected with SARS-CoV-2, the virus that causes COVID-
19, have not been likely to develop ADE upon repeat exposure. This is true of
other coronaviruses as well. Likewise, studies of vaccines in the laboratory with
animals or in the clinical trials in people have not found evidence of ADE.
Following the experience with dengue vaccine, early during the COVID-19
pandemic, concerns about ADE were top of mind. During this time, a few
scientists tried to predict whether ADE would occur by evaluating genes for
similarities and differences. While this was a useful approach at a time when we
did not have much information about what might happen in people, we have
since accumulated several lines of clinical evidence that confirm ADE is not an
issue for COVID-19 or the vaccines:
1. People who are infected with SARS-CoV-2, or its variants, do not become
more susceptible to ADE.
2. Many vaccinated people have been exposed to the virus, and its variants,
and most of them have developed no disease or mild symptoms. A very
small number have experienced more severe disease (“breakthrough
infection”), and these individuals have not shown evidence of ADE.